IMP4297 in Combination With Temozolomide in Patients With Advanced Solid Tumors and Small Cell Lung Cancer

NCT04434482 | Completed Phase 1 FDA Drug

• 1 other identifier: IMP4297-106
• Study Type: interventional
• Target: 59
• Locations: 5 countries
• Sites: 21

Brief Summary

This is an open-label, multi-center, dose-escalation and dose-expansion phase I study to evaluate the safety, tolerability, PK characteristics and anti-tumor activity of PARP inhibitor IMP4297 and temozolomide combination therapy in patients with advanced solid tumors and with ES-SCLC who develops disease progression after 1L platinum-based regimen.

Conditions

Advanced Solid Tumours; Small Cell Lung Cancer

Outcome Measures

Primary Outcomes (4)

• Part I: Dose Escalation safety and tolerability

  TEAEs, vital signs, physical examinations, electrocardiogram (ECG), laboratory tests (including serum chemistry, hematology, and urinalysis, coagulation), etc.

  From signing ICF until safety follow-up

• Part I: Dose Escalation MTD

  the maximum tolerated dose:the highest dose level at which \<1/3 patients experience DLT

  from the initiation of study drugs until the end of dose escalation phase(approximately 1 year)

• Part I: Dose Escalation RP2D

  the recommended phase 2 dose

  from the initiation of study drugs until the end of dose escalation phase(approximately 1 year)

• Part II: Dose Expansion Overall Response Rate (ORR)

  the percentage of patients who had a best response rating of CR and PR which was maintained ≥4 weeks from the first manifestation of that rating.

  from the initiation of study drugs until documented disease progression, withdrawal of consent, loss to follow-up, death, initiation of new anti-cancer treatment or termination of study, which occurs first.

Secondary Outcomes (7)

• Part I: Dose Escalation plasma PK profile of IMP4297 and temozolomide

  Cycle 1 Day 1, Cycle 1 Day 15,Cycle 2 Day 1,Any cycle after cycle 2,unscheduled visit

• Part I: Dose Escalation anti-tumor activity

  from the initiation of study drugs until documented disease progression, withdrawal of consent, loss to follow-up, death, initiation of new anti-cancer treatment or termination of study

• Part I: Dose Escalation,effect of IMP4297 on QT interval

  Cycle 1 Day 1,Cycle 1 Day 15,Cycle 2 Day 1,CnD1,EOT, unscheduled visit

• Part II: Dose Expansion safety and tolerability

  From signing ICF until safety follow-up

• Part II: Dose Expansion anti-tumor activity

  from the initiation of study drugs until documented disease progression, withdrawal of consent, loss to follow-up, death, initiation of new anti-cancer treatment or termination of study

Study Arms (1)

IMP4297(senaparib) and temozolomide

EXPERIMENTAL

IMP4297 and temozolomide

Drug: IMP4297(senaparib)

Interventions

IMP4297(senaparib) DRUG

The dose levels will be escalated following a modified 3+3 dose escalation scheme.

Also known as: temozolomide

IMP4297(senaparib) and temozolomide

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• The patient must voluntarily participate in this clinical study and be willing and able to provide written informed consent/assent for the trial.
• Age ≥ 18 years old on the day of signing informed consent form (ICF), males or females
• Patient population:
• In Part I: The patient must have histologically or cytologically confirmed advanced solid tumor that is refractory to standard treatment or for which no standard treatment exists, including but not limited to triple-negative breast cancer (TNBC), SCLC, ovarian cancer (OC) and metastatic castration-resistant prostate cancer (mCRPC).
• In Part II: The patients must be histologically or cytologically confirmed ES-SCLC with disease progression after one and only one course of 1L standard platinum-based therapy. Anti-PD-1 or anti-PD-L1 antibody therapy is acceptable as long as it's part of the 1L treatment. Including platinum sensitive and platinum resistant patients. Platinum sensitive is defined as the relapse-free interval exceeds 90 days after treatment with platinum doublets is completed; The platinum resistant represents disease relapses within 90 days of treatment completion during a chemotherapy-free interval (CFI).
• In Part I: Patients have an ECOG performance status of 0 to 1.
• In Part II: Patients have an ECOG performance status of 0 to 2.
• Patients have a life expectancy of ≥12 weeks.
• In Part II: patients have at least 1 measurable lesion per RECIST v1.1, including a previously irradiated lesion if has progressed since radiotherapy, that can be accurately measured at baseline which is suitable for accurate repeated measurements
• Patients have adequate organ function, as indicated by the following laboratory values (had not received blood transfusion, apheresis infusion, erythropoietin, granulocyte colony-stimulating factor, and other relevant medical support within 28 days before the administration of the IPs
• Female patients should meet at least 1 of the following criteria before they can participate in the study:
• Females who have no childbearing potential (i.e., physiologically incapable of pregnancy), including those who have undergone hysterectomy, bilateral oophorectomy, or bilateral salpingectomy.
• Post-menopausal (total cessation of menses for ≥1 year).
• For those with childbearing potential, they should have a negative serum pregnancy test during the screening period (within 7 days prior to the first dose of the IPs), should not be in lactation, and willing to take effective contraceptive measures throughout the study period, from study entry up to 6 months after the last dose of the IP(s).
• Male patients are eligible to participate in the study if they have undergone vasectomy or agree to use effective methods of contraception from study entry up to 6 months after the last dose of the IP(s).

You may not qualify if:

• Patients with primary tumor in central nervous system (CNS) and active or untreated central CNS metastases and/or carcinomatous meningitis should be excluded. Patients with previously treated brain metastases may participate provided they are clinically stable for at least 4 weeks and, have no evidence of new or enlarging brain metastases and no requirements for corticosteroids 14 days prior to dosing with IPs.
• Patients with serious acute and chronic infections, including:
• Patients with an uncontrolled acute infection, or an active infection requiring systemic treatment, or patients who have received systemic antibiotics within 2 weeks prior to the first dose of the IPs; prophylaxis use of systemic antibiotics treatment for upper tract infection is allowed as long as no violation with the requirement in Section 6.5 Concomitant Therapy.
• Patients who have a known history of human immunodeficiency virus (HIV) infection and/or acquired immunodeficiency syndrome or positive HIV testing should undergo CD4+ T-cell test during the screening period. Patients with CD4+ T-cell counts \< 350 cells/uL are ineligible for enrollment. Patients with unknown HIV infection status who are unwilling to undergo HIV testing should not be enrolled in the study;
• Patients who have known active hepatitis B or C. To be included in the study, patients with hepatitis B virus surface antigen (HBsAg) or hepatitis C virus (HCV) antibody positive test results during screening must be further tested for hepatitis B virus (HBV) DNA titer (excluding patients with a DNA titer of more than 2500 copies \[cps\]/mL or 500 IU/mL) and HCV RNA (excluding patients with an HCV RNA concentration exceeding the lower detection limit of the assay) to exclude active hepatitis B or hepatitis C infection requiring treatment. Hepatitis B virus carriers, patients with stable hepatitis B infection after drug treatment (DNA titer not exceeding 2500 copies \[cps\]/mL or 500 IU/mL) and hepatitis C infected patients who received treatment and achieved sustained virologic response for at least 12 weeks can be enrolled.
• Note: If the lower detection limit of the HBV DNA assay in the study centers is higher than 2500 copies \[cps\]/mL or 500 IU/mL, the patients in the study center with an HBV DNA assay result lower than the lower detection limit of the assay can be enrolled.
• Active tuberculosis
• Patients who have previously received PARP inhibitors.
• Patients who have received strong CYP3A4 inhibitors or inducers prior to the first dose of the IPs (the patient can be enrolled if the elution period prior to the first dose of the IPs is ≥5 half-lives), or patients who need to continue receiving these medications during the study period.
• Patients who have received a live-virus vaccination within 28 days of the planned start of study.
• Patients who have participated a study of an investigational agent and received study therapy or used an investigational device within 28 days of the first dose of treatment.
• Patients have not recovered (i.e., to ≤Grade 1 or to baseline, as evaluated by NCI-CTCAE v5.0) from cytotoxic therapy-induced AEs, except for alopecia.
• Patients who have received anti-cancer chemotherapy, endocrine therapy, herbal/alternative therapies (including Chinese herbal or Chinese medicine or proprietary Chinese medicine), or other anti-cancer systemic treatment (except anti-cancer antibody) within 5 half-lives or 14 days, whichever is longer prior to the first dose of the IPs. Patients who have received anti-cancer antibody within 28 days prior to the first dose of the IPs.
• Patients who have undergone a major surgery within 28 days prior to the study treatment, or have undergone a radical radiotherapy, or have undergone a palliative radiotherapy within 14 days prior to the study treatment, or have used a radioactive drug (Strontium, Samarium, etc.) within 56 days prior to the study treatment.
• In Part II of the study, patients who have other malignancies within 2 years prior to the first dose of the IPs will be excluded. except for radically treated locally curable malignant tumors, such as basal or squamous cell skin cancer, superficial bladder cancer, or prostate, cervical or breast carcinoma in situ.

Sponsors & Collaborators

• Impact Therapeutics, Inc.: lead

Study Sites (21)

GenHarp Clinical Solutions

Evergreen Park, Illinois, 60805, United States

Location

Gabrail Cancer Researh Center

Canton, Ohio, 44718, United States

Location

Mark H. Zangmeister Center

Columbus, Ohio, 43219, United States

Location

Sarah Cannon Research Institute - Tennessee Oncology

Tennessee City, Tennessee, 37203, United States

Location

Border Medical Oncology

Albury, New South Wales, 2640, Australia

Location

Blacktown Hospital

Blacktown, New South Wales, 2148, Australia

Location

Orange Hospital

Orange, New South Wales, 2800, Australia

Location

Peninsula Health Frankston Hospital

Frankston, Victoria, 3199, Australia

Location

Beijing Cancer Hospital

Beijing, 100142, China

Location

Jilin Cancer Hospital

Jilin, 130000, China

Location

Fudan University Shanghai Cancer Center

Shanghai, 200032, China

Location

Hubei Cancer Hospital

Wuhan, 430079, China

Location

Chungbuk National University Hospital

Cheongju-si, 2864, South Korea

Location

The Catholic university of Korea, st. Vincent's Hospital

Gyeonggi-do, 16247, South Korea

Location

Yonsei university health system, Severance Hospital

Seoul, 03722, South Korea

Location

Asan Medical Center

Seoul, 05505, South Korea

Location

China Medical University Hospital

Taichung, 404, Taiwan

Location

National Cheng Kung University Hospital

Tainan, 704, Taiwan

Location

Chi Mei Medical Center

Tainan, 73657, Taiwan

Location

National Taiwan University Hospital

Taipei, 100, Taiwan

Location

Chang Gung Medical Foundation Linko

Taoyuan District, 333, Taiwan

Location

MeSH Terms

Conditions

Small Cell Lung Carcinoma

Interventions

senaparib; Temozolomide

Condition Hierarchy (Ancestors)

Carcinoma, Bronchogenic; Bronchial Neoplasms; Lung Neoplasms; Respiratory Tract Neoplasms; Thoracic Neoplasms; Neoplasms by Site; Neoplasms; Lung Diseases; Respiratory Tract Diseases

Intervention Hierarchy (Ancestors)

Dacarbazine; Triazenes; Organic Chemicals; Imidazoles; Azoles; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: June 14, 2020
• First Posted: June 17, 2020
• Study Start: August 7, 2020
• Primary Completion: April 29, 2024
• Study Completion: April 29, 2024
• Last Updated: September 19, 2024

Record last verified: 2024-05

Data Sharing

• IPD Sharing: Will not share

Locations

KR (4); AU (4); TW (5); CN (4); US (4)